Bio-Rad to Slash Jobs, Shut Facilities in $80–90M Restructuring Push
BIO sits 38% above its 52-week low of $236.73.
Summary
Bio-Rad is launching a restructuring that includes job cuts and facility closures, with pre-tax charges of $80–90 million, mostly for severance and benefits. The plan, expected to be largely complete by the end of fiscal 2027, aims to improve performance and competitive positioning. This follows the company's Q2 earnings beat after the close, where revenue of $651 million topped estimates by $27 million, driven by clinical diagnostics. The restructuring signals a more aggressive cost-cutting stance, likely in response to activist pressure from Elliott Management earlier this year. While the Q2 results were strong, the restructuring charges will weigh on near-term earnings, and investors will watch for details on the scope of job cuts and facility closures in the coming quarters.
At the time of this announcement, BIO was trading at $326.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $236.73 to $343.12. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.